Galmed Pharma (GLMD) Misses Q4 EPS by 5c

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $274 thousand versus the consensus estimate of $290 thousand.

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Yum! Brands (YUM) PT Lowered to $180 at Argus
• INVO Fertility (IVF) Tops Q2 EPS by 105c